CatalystWireBeta

King’s College Hospital to run Steriwave pilot

In brief · summary, not quotable

No summary for this filing – the full text is below.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King's College Hospital (KCH) will be running a pilot of its Steriwave® light-activated antimicrobial technology. KCH, a globally recognized leader in healthcare innovation and one of London's largest teaching hospitals, will be using Steriwave as part of a quality improvement initiative pilot focused on preventing hospital-acquired infections (HAIs). The pilot at KCH is due to start later this year.

Ondine's Steriwave technology is a groundbreaking antimicrobial treatment that uses a proprietary light-activated agent to rapidly eliminate infection-causing pathogens. The agent is applied to each nostril using a nasal swab and then illuminated with a red light laser. The light activates the photodynamic agent, causing an oxidative burst that destroys infection-causing bacteria, viruses and fungi in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance, making it a viable alternative to antibiotics.

In March 2024, Mid Yorkshire Teaching NHS Trust became the first UK institution to adopt Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients. Following its addition to the NHS Supply Chain in June 2024, Steriwave has become more accessible to hospitals and healthcare organizations across England and Wales, facilitating broader adoption of this innovative technology.

About King's College Hospital and King's College Hospital NHS Foundation Trust

King's College Hospital, located in Denmark Hill, Camberwell, is a major teaching hospital and trauma centre, renowned for its pioneering contributions to healthcare. With a rich history of over a century of innovation, King's has been at the forefront of significant medical advancements, including the UK's first bone marrow transplant and the establishment of the world's first voluntary blood donor service. King's College Hospital is managed by King's College Hospital NHS Foundation Trust.

Find out more: www.kch.nhs.uk

About Ondine Biomedical Inc.

About Steriwave

Steriwave is a groundbreaking antimicrobial treatment that uses a light-activated antimicrobial agent to rapidly eliminate a broad spectrum of pathogens, including bacteria, viruses, and fungi. The treatment is administered in a simple two-step process: first, the agent is applied to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light. The light activates the agent, causing an oxidative burst that destroys pathogens within the single 5-minute treatment, offering a robust alternative to traditional antibiotics without the risk of developing resistance.

Ondine Biomedical Inc.

Carolyn Cross, CEO+001 (604) 665 0555
Iskus Health Ltd Stuart Murray, Commercial Director+353 (0) 1 428 7895
Singer Capital Markets (Nominated Adviser and Joint Broker)
Phil Davies, Sam Butcher+44 (0)20 7496 3000
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan+44 (0)20 7653 4000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard+44 (0)77 1000 5910

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note